Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Launched by APOGENIX GMBH · Dec 3, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol
• • ≥18 years of age
• • Patient is admitted to a hospital (max. 72 hours prior to randomization) due to COVID-19 and has a positive SARS-CoV-2 PCR test
• • Clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the WHO 10-point clinical progression scale) with COVID 19 prior to trial treatment
• • Patient agrees to not participate in another clinical trial from screening until day 56
• Exclusion Criteria:
• • Patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.)
• • Patient is anticipated to be discharged from hospital within 48 hours
• • Patient requires anti-inflammatory medicines beyond SoC (SoC are drugs that are approved for treatment of COVID-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization)
• • Patient requires invasive mechanical ventilation
• • Patient is known to have active tuberculosis
• • Patient is known to have hereditary fructose intolerance.
• • Patient is known to have co-infection with Influenza viruses or other viral respiratory infections (respiratory syncytial virus \[RSV\], parainfluenza viruses, respiratory adenoviruses).

Trial Officials